Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F, Eder C, Kohlmann A, Grossmann V, Kowarsch A, Kern W, Haferlach C, Haferlach T. Schnittger S, et al. Among authors: eder c. Haematologica. 2012 Dec;97(12):1890-4. doi: 10.3324/haematol.2012.065375. Epub 2012 Jun 24. Haematologica. 2012. PMID: 22733026 Free PMC article.
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.
Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, Alpermann T, Kohlmann A, Kern W, Haferlach C, Schnittger S. Jeromin S, et al. Among authors: eder c. Haematologica. 2015 Apr;100(4):e125-7. doi: 10.3324/haematol.2014.119032. Epub 2014 Dec 19. Haematologica. 2015. PMID: 25527566 Free PMC article. No abstract available.
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.
Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, Schmid C, Aul C, Staib P, Wendtner CM, Schmitz N, Haferlach C, Haferlach T. Alpermann T, et al. Among authors: eder c. Haematologica. 2016 Feb;101(2):e55-8. doi: 10.3324/haematol.2015.133819. Epub 2015 Oct 15. Haematologica. 2016. PMID: 26471486 Free PMC article. No abstract available.
Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A. Weissmann S, et al. Among authors: eder c. Leukemia. 2012 May;26(5):934-42. doi: 10.1038/leu.2011.326. Epub 2011 Nov 25. Leukemia. 2012. PMID: 22116554
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann HE, Kreuzer KA, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T. Schnittger S, et al. Among authors: eder c. Leukemia. 2013 Jan;27(1):82-91. doi: 10.1038/leu.2012.262. Epub 2012 Sep 11. Leukemia. 2013. PMID: 23018865
The role of different genetic subtypes of CEBPA mutated AML.
Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S. Fasan A, et al. Among authors: eder c. Leukemia. 2014 Apr;28(4):794-803. doi: 10.1038/leu.2013.273. Epub 2013 Sep 23. Leukemia. 2014. PMID: 24056881
195 results